Abstract
The role of tumor necrosis factor-α in the shedding of soluble tumor necrosis factor receptors in endotoxemia was investigated. The appearance of the soluble tumor necrosis factor receptors was assessed in four healthy volunteers following an intravenous injection of tumor necrosis factor-α and in eight chimpanzees after intravenous administration of endotoxin in the absence or presence of concurrent treatment with a neutralizing anti-tumor necrosis factor-α monoclonal antibody. Injection of tumor necrosis factor-α in humans elicited a significant, instantaneous (after 15 min) increase in the plasma concentrations of both types of soluble tumor necrosis factor receptors. In chimpanzees, treatment with the anti-tumor necrosis factor-α antibody completely neutralized endotoxin-induced tumor necrosis factor-α activity. The release of soluble tumor necrosis factor receptors was strongly (80–90%) inhibited in the presence of the neutralizing antibody. Our results indicate that tumor necrosis factor-α is a prime mediator of endotoxin-induced release of its own soluble receptors.
Similar content being viewed by others
References
Bone RC: The pathogenesis of sepsis. Ann Intern Med 115:457–469, 1991
Van der Poll T, Lowry SF: Tumor necrosis factor in sepsis: Mediator of multiple organ failure or essential part of host defense? Shock (in press), 1994
Kull FC Jr, Jacobs R, Cuatrecasas P: Cellular receptor for125I-labeled tumor necrosis factor: Specific binding, affinity labeling, and relationship to sensitivity. Proc Natl Acad Sci USA 82:5756–5760, 1985
Scheurich P, Uecer U, Krönke M, Pfizenmaier K: Quantification and characterization of high-affinity membrane receptors for tumor necrosis factors on human leukemic cell lines. Int Cancer 38:127–133, 1986
Loetcher H, Pan Y-CE, Lahm H-W, Gentz R, Brockhaus M, Tabuchi H, Lesslauer W: Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61:351–369, 1990
Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GHW, Gatanaga T, Granger GA, Lentz R, Raab H, Kohr WJ, Goeddel DV: Molecular cloning and expression of a receptor for tumor necrosis factor. Cell 61:361–370, 1990
Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, Dower SK, Cosman D, Goodwin RG: A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248:1019–1023, 1990
Lewis M, Tartaglia LA, Lee A, Bennett GL, Rice GC, Wong GH, Chen EY, Goeddel DV: Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 88:2830–2834, 1991
Dembic Z, Loetscher H, Gubler U, Pan Y-CE, Lahm H-W, Gentz R, Brockhaus M, Lesslauer W: Two human TNF receptors have similar extracellular, but distinct intracellular domain sequences. Cytokine 2:231–237, 1990
Peetre C, Thysell H, Grubb A, Olsson I: A tumor necrosis factor binding protein is present in human biological fluids. Eur J Haematol 41:414–419, 1988
Olssen I, Lantz M, Nilsson E, Peetre C, Thysell HJ, Grubb A, Adolf G: Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 42:270–275, 1989
Engelmann H, Novick D, Wallach D: Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor factor receptors. J Biol Chem 265:1531–1536, 1990
Seckinger P, Zhang JH, Hauptmann B, Dayer JM: Characterization of a tumor necrosis factor-α (TNF-α) inhibitor: Evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 87:5188–5192, 1990
Gray PW, Barrett K, Chantry D, Turner M, Feldmann M: Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci USA 87:7380–7384, 1990
Heller RA, Song K, Onash MA, Fischer WH, Chang D, Ringold GM: Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor. Proc Natl Acad Sci USA 87:6151–6155, 1990
Nophar Y, Kemper O, Brakebusch C, Engelman H, Zwang R, Aderka D, Holtman H, Wallach D: Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 9:3269–3278, 1990
Kohno T, Brewer MT, Baker SL, Schwartz PE, King MW, Hale KH, Squires CH, Thompson RC, Vannice JL: A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 87:8331–8335, 1990
Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factorα in vitro andin vivo. Proc Natl Acad Sci USA 89:4845–4849, 1992
Spinas GA, Keller U, Brockhaus M: Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia. J Clin Invest 90:533–536, 1992
van der Poll T, Jansen J, van Leenen D, von der Möhlen M, Levi M, ten Cate H, Gallati H, ten Cate JW, van Deventer SJH: Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 168:955–960, 1993
Shapiro L, Clark BD, Orencole SF, Poutsiaka DD, Granowitz EV, Dinarello CA: Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis 167:1344–1350, 1993
Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, The J5 Study Group, Dayer J-M: Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 76:20–23, 1992
Engelman H, Aderka D, Rubinstein M, Rotman D, Wallach D: A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 264:11974–11980, 1989
Seckinger P, Isaaz S, Dayer JM: A human inhibitor for tumor necrosis factor. J Exp Med 167:1511–1516, 1988
Seckinger P, Isaaz S, Dayer JM: Purification and biologic characterization of a tumor necrosis factor-α inhibitor. J Biol Chem 264:11966–11973, 1989
Lantz M, Gullberg U, Nilsson E, Olsson I: Characterizationin vitro of a human tumor necrosis factor-binding protein: A soluble form of a tumor necrosis factor receptor. J Clin Invest 86:1396–1402, 1990
Gatanaga T, Hwang C, Kohr W, Cappuccini F, Lucci III JA, Jeffers EWB, Lentz R, Tomich J, Yamamoto RS, Granger GA: Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrate of human cancer patients. Proc Natl Acad Sci USA 87:8781–8784, 1990
Mohler KM, Torrance DS, Smith CA, Goodwin RC, Stremler KE, Fung VP, Madani H, Widmer MB: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548–1561, 1993
Lantz M, Malik S, Slevin ML, Olsson I: Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2:402–406, 1990
Van der Poll T, Büller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322:1622–1627, 1990
Van der Poll T, Levi M, van Deventer SJH, ten Cate H, Haagmans BL, Biemond BJ, Büller HR, Hack CE, ten Cate JW: Differential effects of anti-tumor necrosis monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 83:446–451, 1993
Jesmok G, Lindsey C, Duerr M, Fournel M, Emerson Jr T: Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli-challenged swine. Am J Pathol 141:1197–1207, 1992
Digel W, Porzsolt F, Schmid M, Herrmann F, Lesslauer W, Brockhaus M: High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest 89:1690–1693, 1992
Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H: Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal cell lines. Proc Natl Acad Sci USA 87:3127–3131, 1990
Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99–105, 1986
Porteu F, Nathan CF: Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172:599–607, 1990
Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan CF: Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. J Biol Chem 226:18846–18853, 1991
Porteu F, Nathan CF: Mobilizable intracellular pool of p55 (type I) tumor necrosis receptors in humans neutrophils. J Leukoc Biol 52:122–124, 1992
Lantz M, Thysell H, Nilsson E, Olsson I: On the binding of tumor necrosis factor (TNF) to heparin and the releasein vivo of the TNF-binding protein I by heparin. J Clin Invest 88:2026–2031, 1991
van Leenen D, van der Poll T, Levi M, ten Cate H, van Deventer SJH, Hack CE, Aarden LA, ten Cate JW: Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 151:2318–2325, 1993
Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumour necrosis factor by its soluble receptors. J Exp Med 175:323–329, 1992
Engelberts I, Moller A, Leeuwenberg JFM, van der Linden CJ, Buurman WA: Administration of tumor necrosis factor alpha (TNF alpha) inhibitors after exposure to TNF alpha prevents development of the maximal biological effect: an argument for clinical treatment with TNF alpha inhibitors. J Surg Res 53:510–514, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jansen, J., van der Poll, T., Levi, M. et al. Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-α antibody. J Clin Immunol 15, 45–50 (1995). https://doi.org/10.1007/BF01489489
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01489489